Observational Study of Treatment Results and Digital Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy CIDP

What this Trial Is About

This observational study focuses on people in the United States diagnosed with chronic inflammatory demyelinating polyneuropathy or polyradiculoneuropathy CIDP who still have impairments, disabilities, or neurological deficits after at least three months of standard care treatment. The study aims to collect real-world data on treatment outcomes and disease progression over time, lasting approximately two years. Enrollment will continue for one year, so participants may be followed for one to two years depending on when they join. Participants in this study do not receive any experimental treatments instead, their ongoing use of standard CIDP therapies such as immunoglobulin, corticosteroids with some exceptions, plasma exchange, and other specified medications are observed. The study involves digital biomarker collection and integrated treatment outcome monitoring to understand changes in disability and neurological function over the study period. During the study, participants will have their disability and neurological status assessed using tools like the I-RODS and adjusted INCAT scores at baseline and throughout the follow-up. Researchers will collect laboratory tests, comorbidity data, and responses to treatment changes as they occur. Follow-up will continue up to two years from the start of the study, with data collected remotely and through medical records to evaluate disease progression and treatment response.

Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)